Reimbursement code strategy is now a Series A topic

What changed

Enough device companies have hit clearance without a clear payment pathway that the market has repriced the risk. A cleared device without a code is now treated as an unfinished product.

What to prepare

A one-page code strategy — target CPT category, evidence plan, timeline to payment, and interim cash-pay or bundled options — is now a standard part of every serious device deck.

The upside

Founders who take this seriously early close rounds faster and at better terms. It is the single highest-leverage piece of homework a hardware founder can do before fundraising.

The diligence question that changed everything

Series A investors in medical devices now routinely ask for a written reimbursement code strategy alongside the clinical and regulatory plan, a question that a few years ago would typically have been deferred until well after FDA clearance. This shift reflects a hard-won lesson across the portfolio: a cleared device with no viable payment pathway is a stalled company, and the time required to establish a new code or secure appropriate coverage can rival the time required for clearance itself.

Founders who treat this as a late-stage administrative task rather than an early strategic one consistently find themselves raising a bridge round to survive the coverage gap between clearance and predictable reimbursement, a gap that a written strategy formed at seed stage could have meaningfully shortened.

What a credible strategy document actually contains

Investors are not expecting a guaranteed code by the time of the A round; they are expecting a clear-eyed map of the realistic pathways — whether that is fitting into an existing code, pursuing a new Category III-equivalent designation, or building a value dossier for payer-by-payer coverage negotiation — along with a credible estimate of the timeline and cost for each. A document that only presents the best-case pathway without acknowledging the others reads as inexperience rather than confidence.

The strongest versions of this document also include an early engagement plan with specialty societies and a small number of anchor payers, since code strategy in this sector is rarely won by a single company acting alone; it is usually the product of a coalition that includes the clinical specialty's own advocacy infrastructure.

The upside for teams that get ahead of it

Companies that build reimbursement strategy into their earliest clinical trial design — for instance, capturing the specific economic or utilization endpoints a payer will eventually want to see — tend to reach favorable coverage decisions meaningfully faster than companies that design trials purely for regulatory clearance and only think about payer evidence afterward. The incremental cost of capturing those endpoints early is usually small relative to the delay avoided later.

This earlier discipline also changes the fundraising conversation itself: a founding team with a credible, funded reimbursement plan can raise on a more favorable valuation basis, because the investor is underwriting a shorter and more visible path to a sustainable payment model rather than an open-ended coverage gamble.